Source Fact: Financial Supervisory Service DART / 2024-06-25
Disclosure Type: Major Management Matters Related to Investment Judgment (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its May 2023 Letter of Intent (LOI) following the execution of a definitive formal contract worth approximately KRW 107.5B, officially disclosing the previously confidential European-based counterparty as Kiniksa Pharmaceuticals (UK), Ltd.
📊 1. [Summary of Core Disclosure & Key Figures]
- Amended Original Disclosure: Major Management Matters Related to Investment Judgment initially submitted on May 30, 2023
- Reason for Amendment: Disclosure of withheld information (counterparty identity) upon execution of the definitive formal contract
- Contract Name: Conclusion of Letter of Intent (LOI) for Biopharmaceutical Contract Manufacturing
- Changes in Counterparty Identification:
- Pre-amendment: A pharmaceutical company located in Europe (Withheld under trade secrecy)
- Post-amendment: Kiniksa Pharmaceuticals (UK), Ltd
- Contract Amount: KRW 107,513,583,360 (Fixed amount: USD 81,105,600)
- Applied FX Rate: Fixed at KRW 1,325.60 per USD (The standard proxy rate on the initial disclosure date of May 30, 2023)
- Ratio to Revenue: 3.58% relative to the annual revenue baseline at the time of initial disclosure (KRW 3.00T)
- Contract Period: From the LOI execution date (May 30, 2023) until the execution of the definitive formal contract
- Note: The original stipulation indicating that the counterparty’s profile would remain confidential until the signing of a formal contract has been removed due to contract finalization. The designated contract value has carried legal binding force between both parties since the initial LOI phase.
📈 2. [Expert Insight: Implications for Investors]
- Finalization of Contract Framework: This amendment records the transition from the binding LOI phase into the definitive agreement structure. Since the contract value was already disclosed as legally binding from its inception, this transition represents the completion of the procedural step to finalize localized contract operations rather than shifting from a non-binding status.
- Resolution of Information Asymmetry: The transparent disclosure of the specific identity of the European corporate partner (Kiniksa Pharmaceuticals), which had been restricted due to commercial trade secrecy clauses, helps resolve past structural information asymmetry for market participants.
- Investor Consideration: While the execution of the final contract secures the identity details, the recorded KRW value remains calculated using the historical May 2023 conversion anchor (KRW 1,325.60/$). Consequently, the actual realized revenue denominated in KRW may still undergo variations based on real-time currency fluctuations during future manufacturing and delivery phases.
📝 Editor’s Comment (by K-STOCK Editor)
In the commercial biopharma CMO framework, the translation of a preliminary framework into a definitive agreement accompanied by the partner’s formal reveal serves as a clear procedural validation. This amendment signals that the KRW 107.5 billion framework initiated in May 2023—which possessed legal binding force between both parties from day one—has successfully materialized into its finalized contract layout. With the corporate veil lifted to reveal Kiniksa Pharmaceuticals as the anchor client, Samsung Biologics further strengthens its documented global track record. Although the nominal top-line value of the deal hasn’t changed and general operational executing risks naturally remain for any long-term agreement, replacing a geographic placeholder with a concrete corporate name improves visibility for shareholders tracking the firm’s commercial portfolio.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
